1. Home
  2. IMGN

IMGN

ImmunoGen Inc.

Logo ImmunoGen Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

0

Immunogen Inc is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent.

Founded: 1980 Country:
United States
United States
Employees: N/A City: WALTHAM
Market Cap: 8.7B IPO Year: 1989
Target Price: $25.77 AVG Volume (30 days): 9.0M
Analyst Decision: Buy Number of Analysts: 12
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.31 EPS Growth: N/A
52 Week Low/High: $3.61 - $31.25 Next Earning Date: 02-28-2024
Revenue: $287,614,000 Revenue Growth: 200.83%
Revenue Growth (this year): 253.15% Revenue Growth (next year): 46.00%

Share on Social Networks: